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Background and objective: Mycobacterium tuberculosis has been proposed as a candidate
agent for the cause of sarcoidosis. The QuantiFERON-TB Gold test has a higher specificity
for detecting M. tuberculosis infection than the conventional tuberculin skin test. This
study aimed to investigate the rate of positive QuantiFERON-TB Gold results in Japanese
sarcoidosis patients.
Patients and methods: The QuantiFERON-TB Gold test, an enzyme-linked immunosorbent
assay, was used to assess the levels of interferon-gamma resulting from immune responses
to M. tuberculosis-specific antigens, namely early secretory antigen target 6 and culture
filtrate protein 10, in 90 Japanese sarcoidosis patients.
Results: The QuantiFERON-TB Gold result was positive in 3 of the 90 patients tested.
Conclusion: The positivity rate of QuantiFERON-TB Gold was 3.3% in Japanese sarcoidosis
patients.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The QuantiFERON-TB Gold (QFT) test, a whole blood
interferon-gamma assay, is a new technique for diagnosing
Mycobacterium tuberculosis infection (TBI).1,2 Although the
tuberculin skin test (TST) is the current standard diagnostic
test for detecting latent TBI, it shows low specificity. This
probably arises because its purified protein derivative (PPD)
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in both bacillus Calmette-Gue´rin (BCG) strains and non-
tuberculous mycobacteria (NTM). Since the antigens in the
QFTare early secretory antigen target 6 (ESAT-6) and culture
filtrate protein 10 (CFP-10), which are specific to M.
tuberculosis and absent from BCG vaccine strains and the
majority of NTM species, the QFT can detect latent TBI with
higher specificity than the conventional TST.3,4
Sarcoidosis is a systemic granulomatous disorder of
unknown etiology.5 Due to the clinical and pathological
similarities, mycobacterial infections, especially TBI, have
been proposed as candidates for infectious causes of
sarcoidosis. However, it remains controversial whether
sarcoidosis is caused by M. tuberculosis, since numerous
studies using currently available molecular techniques have
resulted in positive or negative results.5,6 Furthermore, it is
sometimes difficult in practice to distinguish between
sarcoidosis and TBI.5 The TST is unsuitable for detecting
TBI in sarcoidosis patients due to its anergically-depressed
reaction. Burton used interferon-gamma production by
alveolar lymphocytes in response to tuberculosis PPD
stimulation to distinguish sarcoidosis from TBI.7
Recently, Drake et al. reported that one ESAT-6 peptide
was recognized in 8 of 26 sarcoidosis patients using an
enzyme-linked immunospot (ELISPOT) assay.8 The present
study aimed to elucidate the rate of positive QFT results in
Japanese sarcoidosis patients.Methods
Patients and controls
Ninety consecutive patients with sarcoidosis (29 males, 61
females; mean age: 48.7 years) were included in this study.
The diagnosis of sarcoidosis was based on a compatible
clinical picture and histological finding of noncaseating
granulomas.5 Cases were excluded if they had previously
been diagnosed with TBI or had chest radiographic evidence
of healed TBI. None of the patients was under systemic
steroid or immunosuppressive therapy. Our Institutional
Review Board approved the study protocol and each patient
gave written informed consent.Table 1 Characteristics of three patients with positive
result of QuantiFERON-TB Gold test.
Patient 1 2 3
Age (year) 61 56 44
Sex Male Female Male
Affected organs Lung, kidney Lung, eye, skin LungSample collection and TST
A heparinized peripheral blood sample was collected from
each patient. For the TST, 0.1ml of tuberculin PPD
(equivalent to three tuberculin units of PPD-S; Nippon BCG
Manufacturing, Tokyo, Japan) was injected intradermally
and the induration diameter was measured after 48–72 h.Radiological stage I II I
s-ACE (IU/l) 14.3 24.1 21.0
TST (mm) 0 0 0
ESAT-6 (IU/ml) 0.37 0.57 1.00
CFP-10 (IU/ml) 0.05 0.23 0.79
Radiological stage: I, bilateral hilar lymphoadenopathy; II,
bilateral hilar lymphoadenopathy and lung parencymal
involvement; s-ACE, serum angiotensin-converting enzyme;
and TST, tuberculin skin test.Whole blood interferon-gamma assay
Interferon-gamma production in whole blood was measured
using the QFT, a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Cellestis, Carnegie,
Australia). The assay was performed by a blinded investi-
gator according to the manufacturer’s instructions. We
interpreted the test result as positive if the concentrationof interferon-gamma for either of the antigens was more
than 0.35 IU/ml.4,9Results
All 90 patients had sarcoid lesions in their lungs. TST results
were available in 84 patients, among which two and one
patients showed indurations of 410 and 15mm, respec-
tively. The QFT was performed in all 90 patients, and their
levels of interferon-gamma response to phytohemagglutinin
were at least 0.5 IU/ml. All individual tests were deemed
valid. Among the 90 sarcoidosis patients, the QFT result was
positive in three patients (3.3%; Table 1). Their specimens
were negative for M. tuberculosis by acid fast staining,
culture and PCR evaluation of lung or skin tissues. During a
1-year follow-up, none of the patients developed TBI. There
were no characteristic clinical, radiographic or pathologic
differences between the 3 QFT-positive patients and 87 QFT-
negative patients.Discussion
In the present study, 3 of 90 sarcoidosis patients showed a
positive QFT result. They had no evidence of TBI in
microbiological, radiological and pathological examinations.
The QFT positivity rate in our Japanese sarcoidosis patients
was 3.3%, which was nearly identical to those in healthy
non-sarcoidosis subjects.3,4,9–12
Although there is no definitive method for diagnosing
latent TBI, many studies have evaluated the specificity of
the QFT in low-risk subjects. Some surveys mainly targeted
students, while others contained middle-aged subjects with
no identified risks for M. tuberculosis exposure.3,4,9–12 In a
Japanese survey, the specificity of the QFT for a BCG-
vaccinated group was reported to be 98.1%.4 Another
Japanese investigation showed that 94% of healthy volun-
teers were negative for the QFT.9 Currently, the high
specificity of the QFT is recognized independently of BCG
vaccination status and age in low-risk groups.3,4,9–12 In the
present study, three patients showed a positive QFT
response (3.3%). Compared with previous data targeting
various TB-prevalent countries and study populations,3,4,9–13
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non-sarcoidosis subjects.
In this study, we cannot provide a link between Japanese
sarcoidosis patients and TBI detected using the QFT, which does
not directly imply or exclude the possibility that M. tubercu-
losis causes sarcoidosis. The results of the QFT are reflected
by the exposure level and amount of M. tuberculosis. If
M. tuberculosis causes sarcoidosis in a non-infectious fashion
and in trace quantities, the release of interferon-gamma may
be below the detection limit of the QFT. Moreover, sarcoidosis
is an immune disease that may not require continuous antigen
exposure. In contrast to our results, surprisingly, Drake et al.
reported that one ESAT-6 peptide was recognized in 8 of 26
sarcoidosis patients.8 They performed an ELISPOT assay with
ESAT-6 and their original KatG peptide, and found that these
mycobacterial antigens induced T-cell responses in the blood of
sarcoidosis patients. Therefore, they suggested immunologic
links between mycobacteria and sarcoidosis. However, there
are many differences between their study and the present
study. First, they targeted mainly African-Americans and more
than half of their patients received certain immunosuppressive
drugs. Second, the ESAT-6 peptides in their ELISPOTassay were
different from the seven types of proteins in our commercially
available ELISA kit. Improving the sensitivity of the test and
studies in various areas and races are required to clarify
the involvement of M. tuberculosis in the pathogenesis of
sarcoidosis.
Conflict of interest
On behalf of all the authors (N. Inui, T. Suda, and K. Chida), I
report that all the authors have no conflict of interest,
including financial, personal, academic and intellectual issues.
References
1. Arend SM, Andersen P, van Meijgaarden KE, et al. Detection of
active tuberculosis infection by T cell responses to early-
secreted antigenic target 6-kDa protein and culture filtrate
protein 10. J Infect Dis 2000;181:1850–4.
2. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing
and spatial tracking of Mycobacterium tuberculosis infection byenumeration of antigen-specific T cells. Lancet 2001;357:
2017–21.
3. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P.
Comparison of tuberculin skin test and new specific blood test in
tuberculosis contacts. Am J Respir Crit Care Med 2004;170:
65–9.
4. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of
tuberculosis infection: an interferon-gamma-based assay using
new antigens. Am J Respir Crit Care Med 2004;170:59–64.
5. Statement on sarcoidosis. Joint Statement of the American
Thoracic Society (ATS), the European Respiratory Society (ERS)
and the World Association of Sarcoidosis and Other Granuloma-
tous Disorders (WASOG) adopted by the ATS Board of Directors
and by the ERS Executive Committee. Am J Respir Crit Care Med
1999;160:736–55.
6. Drake WP, Newman LS. Mycobacterial antigens may be
important in sarcoidosis pathogenesis. Curr Opin Pulm Med
2006;12:359–63.
7. Burton BJ, Breen RA, Janossy G, Acheson JF, Lipman MC. Use of
pulmonary interferon {gamma} responses to mycobacterial
antigen to distinguish sarcoid associated optic neuropathy from
tuberculosis. Br J Ophthalmol 2006;90:802–3.
8. Drake WP, Dhason MS, Nadaf M, et al. Cellular recognition of
Mycobacterium tuberculosis ESAT-6 and KatG peptides in
systemic sarcoidosis. Infect Immun 2007;75:527–30.
9. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M.
Clinical reevaluation of the F TB-2G test as a diagnostic method
for differentiating active tuberculosis from nontuberculous
mycobacteriosis. Clin Infect Dis 2006;43:1540–6.
10. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the
tuberculin skin test and the whole-blood interferon gamma
assay for the diagnosis of latent tuberculosis infection in an
intermediate tuberculosis-burden country. JAMA 2005;293:
2756–61.
11. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial
interferon-gamma assays for diagnosing Mycobacterium tuber-
culosis infection. Eur Respir J 2006;28:24–30.
12. Taggart EW, Hill HR, Ruegner RG, Litwin CM. Evaluation of an in
vitro assay for interferon gamma production in response to the
Mycobacterium tuberculosis-synthesized peptide antigens ESAT-
6 and CFP-10 and the PPD skin test. Am J Clin Pathol 2006;
125:467–73.
13. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two
interferon-gamma assays and tuberculin skin test for tracing
tuberculosis contacts. Am J Respir Crit Care Med 2007;175:
618–27.
